SILENCE THERAP. SP.ADR/1 (XRP2) — Cash Flow-to-Debt Ratio
Latest as of December 2025:
-0.25x
SILENCE THERAP. SP.ADR/1 (XRP2) has a Cash Flow-to-Debt Ratio of -0.25x as of December 2025, meaning its operating cash flow of €-17.29 Million could theoretically repay 0% of its total liabilities (€69.14 Million) in one year. See SILENCE THERAP. SP.ADR/1 free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
-0.25x
Operating CF / Total Liabilities
Operating Cash Flow
€-17.29 Million
EUR
Total Liabilities
€69.14 Million
EUR
Data as of
Dec 2025
Most recent filing
SILENCE THERAP. SP.ADR/1 Cash Flow-to-Debt Ratio (2021–2025)
Historical debt coverage capacity for SILENCE THERAP. SP.ADR/1 across 5 annual periods. For the full cash flow conversion analysis, see XRP2 cash flow metrics.
Annual Cash Flow-to-Debt Ratio for SILENCE THERAP. SP.ADR/1 (2021–2025)
Year-by-year debt coverage analysis for SILENCE THERAP. SP.ADR/1.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.90x | €-62.27 Million | €69.14 Million | ▲ +8.6% |
| 2024 | -0.99x | €-67.64 Million | €68.61 Million | ▼ -94.2% |
| 2023 | -0.51x | €-49.46 Million | €97.45 Million | ▲ +8.0% |
| 2022 | -0.55x | €-57.04 Million | €103.38 Million | ▼ -810.7% |
| 2021 | 0.08x | €9.19 Million | €118.32 Million | — |
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.